121 related articles for article (PubMed ID: 6736871)
1. Cytotoxicity of a cell-reactive immunotoxin containing ricin A chain is potentiated by an anti-immunotoxin containing ricin B chain.
Vitetta ES; Fulton RJ; Uhr JW
J Exp Med; 1984 Jul; 160(1):341-6. PubMed ID: 6736871
[TBL] [Abstract][Full Text] [Related]
2. Ricin B chain-containing immunotoxins prepared with heat-denatured B chain lacking galactose-binding ability potentiate the cytotoxicity of a cell-reactive ricin A chain immunotoxin.
Wawrzynczak EJ; Drake AF; Watson GJ; Thorpe PE; Vitetta ES
Biochim Biophys Acta; 1988 Aug; 971(1):55-62. PubMed ID: 2841982
[TBL] [Abstract][Full Text] [Related]
3. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins.
Fulton RJ; Uhr JW; Vitetta ES
J Immunol; 1986 Apr; 136(8):3103-9. PubMed ID: 3958490
[TBL] [Abstract][Full Text] [Related]
4. Synergy between immunotoxins prepared with native ricin A chains and chemically-modified ricin B chains.
Vitetta ES
J Immunol; 1986 Mar; 136(5):1880-7. PubMed ID: 2419417
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.
Raso V; Ritz J; Basala M; Schlossman SF
Cancer Res; 1982 Feb; 42(2):457-64. PubMed ID: 6948605
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.
Derocq JM; Casellas P; Laurent G; Ravel S; Vidal H; Jansen F
J Immunol; 1988 Oct; 141(8):2837-43. PubMed ID: 3262669
[TBL] [Abstract][Full Text] [Related]
7. Specific cytotoxicity of a human immunoglobulin-directed Fab'-ricin A chain conjugate.
Raso V; Griffin T
J Immunol; 1980 Dec; 125(6):2610-6. PubMed ID: 7430640
[TBL] [Abstract][Full Text] [Related]
8. Synergy of ricin A chain-containing immunotoxins and ricin B chain-containing immunotoxins in in vitro killing of neoplastic human B cells.
Vitetta ES; Cushley W; Uhr JW
Proc Natl Acad Sci U S A; 1983 Oct; 80(20):6332-5. PubMed ID: 6578512
[TBL] [Abstract][Full Text] [Related]
9. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Fulton RJ; Uhr JW; Vitetta ES
Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
[TBL] [Abstract][Full Text] [Related]
10. Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin.
Kernan NA; Knowles RW; Burns MJ; Broxmeyer HE; Lu L; Lee HM; Kawahata RT; Scannon PJ; Dupont B
J Immunol; 1984 Jul; 133(1):137-46. PubMed ID: 6609971
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
12. Internalization of the cytotoxic molecules of T101 F(ab')2-(ricin-A-chain) immunotoxin into human T-leukemic cells.
Ravel S; Casellas P
Eur J Biochem; 1990 Sep; 192(2):469-73. PubMed ID: 2209602
[TBL] [Abstract][Full Text] [Related]
13. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
Shen GL; Li JL; Vitetta ES
J Immunol; 1994 Mar; 152(5):2368-76. PubMed ID: 8133047
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores.
Casellas P; Bourrie BJ; Gros P; Jansen FK
J Biol Chem; 1984 Aug; 259(15):9359-64. PubMed ID: 6746651
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
[TBL] [Abstract][Full Text] [Related]
16. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
Zovickian J; Johnson VG; Youle RJ
J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
[TBL] [Abstract][Full Text] [Related]
17. [Selective cytotoxicity of an antibody-ricin A chain conjugate for human tumor cells].
Tonevitskiĭ AG
Mol Biol (Mosk); 1985; 19(4):1034-41. PubMed ID: 4047033
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity of fresh leukemic cells to T101 ricin A-chain immunotoxin: a comparative study between Fab fragment and whole Ig conjugates.
Chiron M; Derocq JM; Kuhlein E; Roubinet F; Demur C; Grandjean H; Huguet F; Jaffrezou JP; Jansen F; Laurent G
Leuk Res; 1989; 13(6):491-9. PubMed ID: 2788783
[TBL] [Abstract][Full Text] [Related]
19. Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates.
Killen JA; Lindstrom JM
J Immunol; 1984 Nov; 133(5):2549-53. PubMed ID: 6332854
[TBL] [Abstract][Full Text] [Related]
20. Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2.
Better M; Bernhard SL; Lei SP; Fishwild DM; Lane JA; Carroll SF; Horwitz AH
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):457-61. PubMed ID: 7678457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
